Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by Aclaris Therapeutics, Inc. on June 7, 2018. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 30,906,003 shares outstanding, 28,050,902 shares (90.76%) were present or represented by proxy. Two proposals were submitted and approved:
- Proposal 1: Election of Directors
- Christopher Molineaux: 20,633,234 votes For; 4,780,034 votes Withheld.
- Bryan Reasons: 25,344,199 votes For; 69,069 votes Withheld.
- Broker Non-Votes: 2,637,634.
- Outcome: All nominees were elected.
- Proposal 2: Ratification of Auditors
- PricewaterhouseCoopers LLP: 28,037,542 votes For; 11,906 votes Against; 1,454 Abstained.
- Outcome: Appointment ratified for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 26, 2018, for detailed background on the director nominees and auditor appointment.
- Confirm the total share count and record date details referenced in the proxy statement.
- Review the significant number of votes withheld for Christopher Molineaux (approximately 18.7% of votes cast) compared to Bryan Reasons.